Plain-English reading on the vagus nerve, its science and how to look after it
How It Works

The Impact of Vagus Nerve Stimulation on Frog Heart Function

A flat folk-art vector illustration of a frog heart encircled by a spiral of stylised poppies, tulips and olive sprigs on a white background.


On the night of Easter Saturday 1921, a pharmacologist named Otto Loewi woke from a dream with the design for an experiment that would settle one of neuroscience’s most contentious debates: whether nerves communicate with their targets electrically or chemically. He went to his laboratory, isolated two beating frog hearts, stimulated the vagus nerve of the first, collected the fluid bathing it, and transferred that fluid to the second heart. The second heart slowed — not because any nerve touched it, but because a chemical substance released by the vagus nerve had crossed from one chamber to the other. Loewi called this substance “Vagusstoff.” It was later identified as acetylcholine, and it became the first neurotransmitter ever discovered. That single frog-heart experiment launched the field of chemical neurotransmission and, a century later, its intellectual descendants include vagus nerve stimulators approved by the FDA for epilepsy, depression, and rheumatoid arthritis.

The Experiment That Changed Neuroscience

By 1921, the debate over neural communication had lasted decades. One camp — the “sparks” — argued that nerves transmitted signals electrically, like wires. The other — the “soups” — proposed that nerves released chemical substances at their terminals. The electrical camp had the weight of convention behind it: action potentials had been measured, and the speed of nerve conduction seemed too fast for a chemical intermediary. The chemical camp had suggestive pharmacological evidence but no direct proof.

Loewi’s experiment was elegant in its simplicity. He isolated two frog hearts, each still beating in a chamber of Ringer’s solution (a saline that keeps excised hearts functioning). The first heart retained its vagus nerve; the second was denervated. He electrically stimulated the vagus nerve of the first heart. As expected, it slowed. He then pipetted the Ringer’s solution from the first heart’s chamber into the second heart’s chamber. The second heart slowed too — despite having no nerve connection to anything. The only explanation was that the vagus nerve had released a substance into the fluid, and that substance acted on cardiac muscle directly.

Loewi repeated the experiment with the accelerator nerve (the sympathetic cardiac nerve). Stimulating it sped up the first heart, and the transferred fluid sped up the second. He called the inhibitory substance Vagusstoff and the excitatory substance Acceleransstoff. The symmetry was important: two different nerves released two different chemicals, each with a specific and reproducible effect on the heart. This was not a nonspecific artefact — it was targeted chemical signalling.

The Dream — and the Science Behind the Story

Loewi’s own account of the experiment’s origin is among the most famous anecdotes in science. He wrote that the experimental design came to him in a dream on Easter Saturday night. He woke, scribbled notes, and fell back asleep. By morning, the notes were illegible. The next night, the dream returned. This time he rose at 3 a.m. and went directly to the laboratory.

The dream story has become inseparable from the science, but colleagues noted that Loewi had a flair for dramatic retelling. Henry Dale, who would share the Nobel Prize with him, recalled a more prosaic version: Loewi woke the second night, took careful notes, and ran the experiment the following day — not at 3 a.m. What is undisputed is that the idea did not come from nowhere. In 1902, while working at University College London, Loewi had met both Dale and Thomas R. Elliott. Elliott had already proposed that sympathetic nerves released adrenaline, an idea considered radical at the time. The concept of chemical transmission had been percolating in Loewi’s thinking for nearly two decades before the experiment that proved it.

One detail that Loewi himself acknowledged: the experiment’s success depended on conditions he did not fully control. Acetylcholine is rapidly broken down by the enzyme acetylcholinesterase. Had the frog’s cholinesterase activity been slightly higher — as it is in some species and at higher temperatures — the substance would have been degraded before reaching the second heart. Loewi conducted the experiment in winter, using cold frog hearts, which slowed enzymatic breakdown enough for the chemical to survive the transfer. A summer experiment might have failed, and the history of neuroscience might have taken a different path.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

From Vagusstoff to Acetylcholine

Loewi demonstrated that Vagusstoff existed and that it slowed the heart. Identifying its chemical structure fell to Henry Dale in London. Dale had been studying the pharmacology of acetylcholine — a compound first synthesised by Arthur Ewins in 1914 — and had characterised its two distinct modes of action. At low doses, acetylcholine mimicked the effects of muscarine (a mushroom toxin that slows the heart and stimulates glands). At higher doses, it mimicked nicotine (stimulating skeletal muscle and autonomic ganglia). Dale named these the muscarinic and nicotinic actions of acetylcholine, a classification that remains the foundation of cholinergic pharmacology today.

Dale’s critical contribution was proving that Vagusstoff and acetylcholine were the same molecule. By the mid-1930s, the evidence was conclusive: the vagus nerve releases acetylcholine at its cardiac terminals, acetylcholine binds to muscarinic receptors (now classified as M2 subtype) on sinoatrial node cells, and this binding opens GIRK potassium channels that hyperpolarise the cell membrane, slowing the heart’s pacemaker rhythm. The speed of this effect — measurable within 200 milliseconds of vagal stimulation — explains why the vagal brake on heart rate is so much faster than the sympathetic accelerator, which operates through slower second-messenger cascades.

In 1936, Loewi and Dale shared the Nobel Prize in Physiology or Medicine “for their discoveries relating to chemical transmission of nerve impulses.” Dale also predicted the existence of an enzyme that rapidly metabolises acetylcholine at the synapse — acetylcholinesterase — which was later confirmed and became the target of drugs ranging from myasthenia gravis treatments to nerve agent antidotes.

Why Frog Hearts Were the Right Model

The frog heart was not an arbitrary choice. Three features made it uniquely suited to this experiment. First, frog cardiac muscle is myogenic — it generates its own electrical rhythm and continues beating after removal from the body, as long as it is kept in oxygenated saline. This allowed Loewi to work with isolated hearts for extended periods without the complexity of maintaining blood flow. Second, the frog vagus nerve is accessible and easy to dissect, with a clear anatomical path from the brainstem to the heart. Third, and most critically, frog hearts have lower cholinesterase activity than mammalian hearts, particularly at low temperatures. This gave the released acetylcholine enough survival time to diffuse through the Ringer’s solution to the second heart.

Mammalian hearts would have been far more difficult. Their cholinesterase activity is high enough that acetylcholine is broken down within milliseconds of release — fast enough to prevent the substance from accumulating in a bath solution. The very property that makes mammalian cholinergic transmission precise and localised would have made it invisible to Loewi’s experimental design. Later researchers confirmed Loewi’s findings in mammals using cholinesterase inhibitors to block the enzyme, allowing acetylcholine to accumulate to detectable levels.

Frog hearts remain a teaching tool in physiology laboratories worldwide. The classic Loewi experiment — stimulate the vagus, transfer the fluid, observe the response — is still performed by students as an introduction to neurotransmission, and the setup has changed remarkably little in a century.

The Line from Loewi to Modern Vagus Nerve Medicine

The discovery that the vagus nerve communicates through acetylcholine set the stage for every subsequent advance in vagus nerve science. The lineage is direct and traceable.

In the 1990s, Kevin Tracey and colleagues at the Feinstein Institutes discovered that vagal stimulation could suppress systemic inflammation — a finding that seemed to have nothing to do with heart rate. The mechanism turned out to be acetylcholine acting on a different receptor in a different organ. Vagal efferent fibres release acetylcholine in the spleen, where it binds to alpha-7 nicotinic acetylcholine receptors on macrophages. This binding suppresses the production of tumour necrosis factor (TNF), interleukin-1, and interleukin-6 — the same pro-inflammatory cytokines that drive rheumatoid arthritis, inflammatory bowel disease, and sepsis. Tracey named this the cholinergic anti-inflammatory pathway.

The pathway Tracey described uses the same neurotransmitter Loewi discovered, released by the same nerve, acting on a receptor subtype that Dale classified. In July 2025, the FDA approved SetPoint Medical’s implantable vagus nerve stimulator for rheumatoid arthritis — the first VNS device approved for an autoimmune condition. The pivotal trial showed that 60 seconds of daily vagal stimulation reduced RA symptoms in patients who had failed biologic drugs. The mechanism is Vagusstoff, working through Dale’s nicotinic receptor subtype, suppressing the inflammatory mediators that Tracey identified. A century of science, traced back to two frog hearts in Ringer’s solution.

What the Frog Heart Experiment Did Not Show

Loewi’s experiment proved chemical neurotransmission at one specific junction — the vagal innervation of the heart. It did not prove that all synapses are chemical. In fact, electrical synapses (gap junctions) were later discovered and remain functionally important in the brain and heart. The modern understanding is that both mechanisms coexist: most synapses in the nervous system are chemical, but electrical synapses provide faster, bidirectional coupling where millisecond synchronisation is required.

The experiment also did not explain how the vagus nerve influences the dozens of other organs it innervates. The vagus carries approximately 100,000 fibres — a mix of myelinated A and B fibres and unmyelinated C fibres — serving the heart, lungs, oesophagus, stomach, liver, intestines, and spleen. Each organ receives its own subset of vagal fibres, and the neurotransmitter dynamics at each target are different. The heart receives fast-acting muscarinic signalling; the gut receives a complex mix of excitatory and inhibitory signals through the myenteric and submucosal plexuses; the spleen receives the nicotinic anti-inflammatory signal. Loewi showed one piece of a system that would take another century to map, and the mapping is still incomplete — the Feinstein Institutes’ REVA project, launched to create the first comprehensive 3D atlas of vagus nerve fibre organisation using microCT and immunohistochemistry, reported initial results from 30 donor nerves in 2026.

What Loewi did establish, irrevocably, was the principle: nerves talk to their targets by releasing chemicals. That principle made modern pharmacology possible. Every drug that acts on a receptor, every neurotransmitter system mapped in the brain, every neuromodulation device that works by triggering or blocking chemical signalling — all descend from the night a pharmacologist dreamed about two frog hearts in a dish.

The vagus nerve’s story began with Loewi’s frog hearts and has expanded into one of medicine’s most active frontiers — from epilepsy treatment to bioelectronic anti-inflammatory therapy. My Vagus Nerve & Me traces the full arc, from the anatomy Loewi dissected to the clinical applications his discovery made possible, and explains what it means for your health today. Get My Vagus Nerve & Me eBook and understand the nerve that started a revolution in how we think about the body.